Jaguar Health Partners with B2i Digital for Innovative Investor Engagement Campaign
Developing First-In-Class Plant-based Medicines for GI Disease
Jaguar Health, Inc. (Nasdaq: JAGX) and its family company Napo Pharmaceuticals (Napo) is a commercial-stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with GI distress, specifically overactive bowel, which includes symptoms such as chronic debilitating diarrhea, GI urgency, and GI incontinence.
Napo's main product is crofelemer, an FDA-approved plant-based prescription drug for HIV-related diarrhea extracted from trees sustainably harvested in the Amazon rainforest. The most critical near-term catalysts are the expected availability in late Oct. 2023 of top-line results of Napo’s Phase 3 clinical trial to expand crofelemer into the preventative treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy, and the generation of proof-of-concept data by the end of 2023 and in 2024 to expand crofelemer into two rare disease indications: short bowel syndrome (SBS) and microvillus inclusion disease (MVID) with intestinal failure.
We are excited to have Jaguar Health join the B2i Family of Featured Companies and invite you to visit their B2i Digital profile page to learn more: https://b2idigital.com/jaguar-health.
Jaguar Health offers several key strengths for investors to consider:
Jaguar Health is developing multiple formulations of its key product, crofelemer, to treat different gastrointestinal diseases.
Canalevia-CA1 is the first and only product indicated for CID in dogs to receive any type of approval from the FDA.
Beyond its core focus, Jaguar Health has invested in an intriguing new venture targeting mental health disorders through natural plant-based prescription drugs.
GRI Bio Joins B2i Digital to Deploy Cutting-Edge Engagement Campaign
GRI Bio, Inc. (NasdaqCM: GRI) is a clinical-stage biotechnology company developing novel immunotherapies that modulate natural killer T (NKT) cells.
GRI Bio’s lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for treating idiopathic pulmonary fibrosis, a serious disease with significant unmet needs. The Company is also developing a pipeline of novel type 2 NKT agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline.
We are proud to welcome GRI Bio into the B2i Digital family. To learn more about GRI Bio, visit their B2i Digital profile at: https://b2idigital.com/gri-bio.
GRI Bio offers several key strengths for key stakeholders to consider:
Lead iNKT inhibitor GRI-0621 launching Phase 2a biomarker study with interim data expected H1 2024 and topline data H2 2024.
GRI’s second clinical candidate, GRI-0803, is focused on systemic lupus erythematosus (SLE). GRI is targeting an IND filing in H1 2024 with topline data from Phase 1 a/b expected H2 2024.
Seasoned leadership team with proven R&D expertise in the biotech industry and a track record of developing novel therapeutics from concept to clinic.
Our B2i Digital Profiles seamlessly integrate essential data feeds for press releases, stock charts, stock details, financials, and SEC filings. These invaluable feeds are provided by our esteemed colleagues, Joe Dunlow and Amy Ostler, from B2i Technologies.
To bring your website to life with real-time data and other website enhancements, contact amy.ostler@b2itech.com
Benchmark's Exclusive Investor Conferences Offer Direct Access To Dynamic Growth Companies
B2i Digital is delighted to announce our new collaboration with The Benchmark Company, LLC. The B2i Digital Team has been working hard to prepare the platform for showcasing this conference marketing partnership.
Benchmark is hosting investor conferences that facilitate one-on-one and small-group engagement with executive teams from dynamic public companies across key sectors.
The Consumer One-on-One Conference takes place on September 7, featuring over 20 dynamic consumer brands. The 10th Annual TMT One-on-One Conference occurs on September 13-14, showcasing over 40 cutting-edge tech, media, and telecom companies. The 12th Annual Discovery One-on-One Conference on December 7 will allow investors to engage with companies across a wide range of high-growth industries.
The small-group format of Benchmark's conferences facilitates in-depth discussions and valuable insights into operations and future prospects. Attendees can discover promising growth stories early through nuanced conversations with company representatives.
Benchmark maintains a longstanding commitment to connecting high-potential companies with aligned investors. We hope you can attend one of these exclusive events for direct access to innovative companies shaping the future.
ROTH MKM’s 10th Annual Solar & Storage Symposium offers direct access to executive teams from cutting-edge public and private companies across the solar and storage value chain. B2i Digital is proud to be a Marketing Sponsor. This must-attend event, held September 12-13, 2023, alongside Solar Power International in Las Vegas, Nevada, will facilitate one-on-one and small group meetings between investors and approximately 25 innovative companies shaping the future of solar and energy storage. ROTH MKM is committed to providing an intimate, small-group format that enables in-depth discussions and valuable insights into operations and future prospects.
Discover the most promising solar and storage innovations through thoughtful conversations with company presenters at this premier industry event.
B2i Digital, Inc. provides digital marketing support to the above-mentioned Featured Companies, the Featured Companies hosted on b2idigital.com, and the Featured Conference companies hosted on b2idigital.com. B2i Digital has not independently verified the accuracy of the information contained herein or on b2idigital.com. The content was provided by the Companies or publicly available sources. B2I Digital, Inc. makes no warranties as to the accuracy of any information provided. No content contained herein or on b2idigital.com shall be considered an offer to solicit the sale of any security or be considered as an opinion as to its investment suitability. Please reference the full disclaimer at https://b2idigital.com/disclaimer.
Crafting this email was quite a task as we had a vast array of topics to cover, and I wanted to ensure fairness throughout. The sequence in which I mentioned our valuable alliances with Roth MKM, Benchmark, GRI Bio, and Jaguar Health above does not indicate their respective significance. In case you didn't notice, I have deliberately flipped the order of our partners in this paragraph and in the subject line to emphasize the equal importance we place on all our esteemed partners.
We trust that you will find value in these exceptional events and the latest featured companies as you navigate the sometimes unpredictable landscape of the US capital markets.
Wishing you a rejuvenating, rewarding, and fun-filled Labor Day weekend as we gear up for an exciting transition from the unofficial summer season.
David Shapiro Chief Executive Officer B2i Digital, Inc. 212-579-4844 (office) 917-806-4171 (cell)
